Casdin Capital

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Biopharmaceutical research and development company that's an affiliate of Clover Health

Remix Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on the research and development of innovative small molecule therapies that reprogram RNA processing to address various diseases. Founded in 2018, the company utilizes a biology platform to identify and prioritize therapeutic targets within RNA processing, aiming to tackle previously undruggable disease drivers. Its REMseq platform assists in validating these targets and optimizing chemical compounds for potential treatments. By analyzing patterns in RNA processing, Remix Therapeutics seeks to modulate gene expression, thereby enabling healthcare providers to correct or enhance genetic messages at their source, ultimately aiming to provide new approaches for treating diseases.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.

Developer of mRNA-based pathway activity profiling technology designed to revolutionize precision medicine by obtaining more insight into the mechanisms of disease. The company offers to utilize its extensive database with pathway activity profiles to support diagnostics and drug development, providing researchers with qPCR tests for decentralized use via a service testing facility in The Netherlands.

22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.

Creyon Bio is a pre-clinical stage company focused on advancing drug development through a data-driven methodology. It specializes in engineering RNA-based medicines and their components by creating proprietary datasets that inform advanced machine learning models. This innovative approach enables the rapid identification of design rules and engineering principles necessary for the development of safe and effective oligonucleotide-based medicines. By leveraging these insights, Creyon Bio aims to improve the efficiency of the drug development process, ultimately contributing to cost savings in the healthcare sector while catering to diverse patient populations.

Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.

Operator of a biotechnology company intended to provide novel small molecule medicines targeting g-protein-coupled receptors. The company provides industrial-scale drug discovery using novel screening technologies and structure-based drug design, enabling medical researchers to easily find patients' treatments for a wide range of diseases.

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Maze Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in the development of genetic modifier therapeutics. Founded in 2017 and formerly known as Modulus Therapeutics, the company is dedicated to translating genetic insights into innovative medicines. Maze Therapeutics utilizes a comprehensive approach that integrates large-scale human genetics data, functional genomics, and various drug discovery methodologies. This approach allows the company to identify modifier genes that offer protection against diseases, enhancing the understanding of target biology and informing drug development strategies. By leveraging these insights, Maze Therapeutics aims to facilitate the creation of novel therapies that can benefit patients.

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.

Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.

Amplo Biotechnology is focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at addressing severe diseases related to the neuromuscular junction, which can lead to paralysis, breathing difficulties, and swallowing challenges. The company targets conditions such as congenital myasthenic syndromes, leveraging its lead program, AAV-Dok7, developed by a research group at the University of Tokyo. The therapies are administered through intravascular injections, initiating molecular processes that enable effective treatment for patients suffering from these rare disorders. Amplo’s mission is to create potentially curative solutions for conditions that significantly impact patient health and quality of life.

Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Thyme Care is a Nashville TN-based provider of oncology care management solutions.

Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. The company is focused on developing small-molecule activators of glucocerebrosidase and advanced programs targeting the innate immune system that can accelerate the progression of several neurological diseases, enabling healthcare professionals to transform the lives of patients with treatments for various ailments.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012 that focuses on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a proprietary bench-top system that allows for the capture, growth, and analysis of primary cells directly from patient blood samples. This technology is designed to enhance the control of cell phenotype and function, thereby optimizing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to empower researchers with advanced tools for cell maintenance and expansion, ultimately facilitating predictive therapy development and improving clinical outcomes.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Zentera Therapeutics is a biopharmaceutical company.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Hexagon Bio, Inc. is a biotechnology company based in Menlo Park, California, that specializes in mining genomic data from fungal genomes to develop targeted small molecule therapeutics for diseases with unmet medical needs. Founded in 2016, the company leverages a proprietary platform that integrates data science, synthetic biology, and automation to discover and engineer novel drugs. By focusing on evolutionarily refined molecules and their corresponding protein targets, Hexagon Bio aims to identify and develop new medicines from the global metagenome, ultimately striving to enhance patient outcomes through innovative therapeutic solutions.

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Operator of a drug discovery platform designed to develop immune based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. The company's platform offers leveraging epigenetic variation and CAR-T precision genetic engineering technology to target tumorous epitopes that are broadly represented across various cancers, enabling patients to get allogeneic treatments to overcome disease.

Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company utilizes insights from its scientific founders to identify "switch sites," which are druggable regions that play a crucial role in regulating transcription factors and addressing disease-related mutations. Flare's innovative drug discovery efforts have led to a promising pipeline of drug programs targeting well-validated transcription factors, with an initial emphasis on precision oncology. The company's platform also holds potential for applications in neurology, rare genetic disorders, immunology, and inflammation, aiming to transform treatment approaches for various diseases.

Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.

Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.

Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

Notch Therapeutics Inc. is an immune cell therapy company based in Toronto, Canada, focused on developing gene-edited allogenic T cell therapies for cancer treatment. Established in 2018, the company utilizes an induced pluripotent stem cell (iPSC) platform that enables precise control of Notch signaling. This innovative technology addresses key limitations in cell therapy development by allowing for the design and manufacture of a consistent supply of therapeutic T cells. Notch Therapeutics specializes in iPSC AlloCAR therapy products aimed at treating conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, enabling healthcare professionals to engineer stem cells tailored to the specific biological challenges presented by complex diseases.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.

Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.

Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.

Faze Medicines is a biotechnology company established in 2020 and based in Cambridge, Massachusetts. The company focuses on developing small molecule drugs targeting the underlying drivers of disease pathology, particularly for conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines leverages innovative research on biomolecular condensates to create potential therapeutic breakthroughs. Through advanced screening and proteomics techniques, the company aims to pioneer new treatments for various diseases, including frontotemporal dementia (FTD) and DM1, thereby addressing significant unmet medical needs.

Developer of cryopreservation system designed to preserve small molecules used in clinical research and studies. The company designs and manufactures patented ice recrystallization inhibitors for use in the cryopreservation of cells, and tissues that maintain cellular function after extended frozen storage, thereby enabling physicians to use less costly storage and transportation systems for cell therapeutics.

iVexSol Inc. is a biotechnology company specializing in the development of lentiviral vector (LVV) manufacturing technology aimed at addressing the shortage of these crucial gene delivery vehicles. Established in 2018 and located in Worcester, Massachusetts, iVexSol focuses on streamlining the manufacturing process for cell and gene therapies (CGTs). The company’s innovative technology simplifies the creation of essential reagents, significantly reducing development time and complexity. This advancement not only accelerates the development of CGTs but also enhances access for researchers and manufacturers in the field.

Operator of a drug discovery platform designed to develop immune based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. The company's platform offers leveraging epigenetic variation and CAR-T precision genetic engineering technology to target tumorous epitopes that are broadly represented across various cancers, enabling patients to get allogeneic treatments to overcome disease.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Cedilla Therapeutics, Inc. is focused on developing targeted small-molecule medicines aimed at treating cancer and other diseases resulting from protein dysregulation. The company leverages unique insights into protein stability to create innovative therapeutic approaches, including direct ligand-induced degradation, disruption of protein-protein interactions, and the identification of upstream regulators that influence protein stability. Cedilla’s technology allows for the mapping of protein susceptibility to enhance endogenous degradation pathways, facilitating the transition from stable to susceptible protein states. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cedilla Therapeutics aims to broaden the applicability of its therapies beyond oncology, addressing a range of conditions associated with protein dysregulation.

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Lyra Health, Inc. is a Burlingame, California-based company that operates a digital platform connecting employers with mental health care providers. Founded in 2015, Lyra Health aims to improve access to effective mental health care for employees by utilizing innovative matching technology. The platform enables members to find personalized care by connecting them to a curated network of therapists and coaches, facilitating live video therapy and offering digital self-care tools. Lyra Health assesses treatment outcomes using clinical measures, such as the PHQ-9 and GAD-7, to monitor symptom improvement for conditions like anxiety and depression. This approach has resulted in significantly higher engagement and better outcomes compared to traditional mental health plans. Through its services, Lyra Health helps employees navigate the mental health system, schedule appointments, and maintain support throughout their treatment journey.

Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies utilizing the principle of synthetic lethality. Established in 2014, the company aims to discover novel drug targets that address driver genes in cancer. Its research is concentrated on three primary areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that surpass the efficacy of single-agent therapies. By leveraging these strategies, Tango Therapeutics seeks to deliver next-generation targeted treatments for patients battling cancer.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.

Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.

Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.

MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.

Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.

Tango Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies utilizing the principle of synthetic lethality. Established in 2014, the company aims to discover novel drug targets that address driver genes in cancer. Its research is concentrated on three primary areas: counteracting the loss of tumor suppressor genes, reversing cancer cells' ability to evade the immune system, and identifying effective drug combinations that surpass the efficacy of single-agent therapies. By leveraging these strategies, Tango Therapeutics seeks to deliver next-generation targeted treatments for patients battling cancer.

Biopharmaceutical research and development company that's an affiliate of Clover Health

Lyra Health, Inc. is a Burlingame, California-based company that operates a digital platform connecting employers with mental health care providers. Founded in 2015, Lyra Health aims to improve access to effective mental health care for employees by utilizing innovative matching technology. The platform enables members to find personalized care by connecting them to a curated network of therapists and coaches, facilitating live video therapy and offering digital self-care tools. Lyra Health assesses treatment outcomes using clinical measures, such as the PHQ-9 and GAD-7, to monitor symptom improvement for conditions like anxiety and depression. This approach has resulted in significantly higher engagement and better outcomes compared to traditional mental health plans. Through its services, Lyra Health helps employees navigate the mental health system, schedule appointments, and maintain support throughout their treatment journey.

Kallyope Inc. is a biotechnology company based in New York that focuses on the gut-brain axis, the complex communication network between the gastrointestinal tract and the brain. Founded in 2014, Kallyope develops innovative therapeutics and consumer products aimed at enhancing human health and nutrition. The company leverages advanced technologies in sequencing, computational biology, neural imaging, and human genetics to gain insights into gut-brain biology. This understanding allows Kallyope to engage in drug discovery efforts that target the fundamental processes of human physiology, with the potential to transform approaches to health and nutrition.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

PACT Pharma, Inc. is engaged in developing personalized cell-based therapies aimed at treating cancer, specifically through neoantigen-specific adoptive TCR T-cell therapies for solid tumors. The company utilizes advanced bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying neoantigen peptides that provoke targeted T cell responses against cancer cells. By recognizing neo-epitopes, which are unique mutations in each patient's cancer, PACT Pharma creates autologous T cells engineered to specifically target and eliminate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is focused on innovative approaches to enhance cancer treatment through tailored immunotherapies.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.

Provider of immunotherapies intended to transform cancer treatment and improve quality of life. The company's cellular immunotherapy platform uses gene therapy to target cancer cells and delivers to any patient, with any tumor, at any time to directly, safely, and controllably attack cancer, enabling medical practitioners to safeguard patients by creating and harnessing a powerful immune response in the body.

Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits. It was founded in 2018 and headquartered in Seattle, Washington.

Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

iVexSol Inc. is a biotechnology company specializing in the development of lentiviral vector (LVV) manufacturing technology aimed at addressing the shortage of these crucial gene delivery vehicles. Established in 2018 and located in Worcester, Massachusetts, iVexSol focuses on streamlining the manufacturing process for cell and gene therapies (CGTs). The company’s innovative technology simplifies the creation of essential reagents, significantly reducing development time and complexity. This advancement not only accelerates the development of CGTs but also enhances access for researchers and manufacturers in the field.

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Codexis, Inc. is an industrial biotechnology company focused on discovering, developing, and selling protein catalysts for pharmaceutical and chemical production. The company offers a range of products, including intermediate chemicals for further processing, biocatalyst panels, and kits for chemistry screening. Codexis also provides protein catalyst screening and engineering services, utilizing its CodeEvolver technology platform to develop protein catalysts capable of performing specific chemical transformations. This platform aids in discovering novel biotherapeutic drug candidates and enhances manufacturing productivity for pharmaceutical companies. Codexis' technologies are currently employed by over 50 pharmaceutical firms to optimize process development from research to manufacturing. Founded in 2002 and headquartered in Redwood City, California, Codexis aims to improve the efficiency and effectiveness of chemical production through biocatalysis.

Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.

Foghorn Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company aims to understand and manipulate gene expression to develop innovative therapies for various diseases, particularly cancer. Foghorn is advancing several drug candidates, including FHD-286, an enzymatic inhibitor targeting BRG1 and BRM for acute myeloid leukemia and uveal melanoma, and FHD-609, a protein degrader aimed at treating synovial sarcoma. Additionally, the company has ongoing preclinical and discovery programs targeting non-small-cell lung cancer and other cancers associated with ARID1B mutations. Foghorn has established a collaboration with Merck Sharp & Dohme Corp. to create novel oncology therapeutics. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics is pioneering a new class of drug targets that could transform treatment approaches for patients with serious diseases.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

Maze Therapeutics is a biotechnology company based in South San Francisco, California, that specializes in the development of genetic modifier therapeutics. Founded in 2017 and formerly known as Modulus Therapeutics, the company is dedicated to translating genetic insights into innovative medicines. Maze Therapeutics utilizes a comprehensive approach that integrates large-scale human genetics data, functional genomics, and various drug discovery methodologies. This approach allows the company to identify modifier genes that offer protection against diseases, enhancing the understanding of target biology and informing drug development strategies. By leveraging these insights, Maze Therapeutics aims to facilitate the creation of novel therapies that can benefit patients.

Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.

Prominex, Inc. is a San Diego-based company that specializes in the development and manufacturing of molecular diagnostic assays for Point-of-Care (POC) infectious disease testing. Established in 2016, Prominex has created the Validex System, which streamlines the diagnostic process by eliminating the need for thermal cycling and various complex components typically required in molecular diagnostics. This innovative system allows for the analysis of crude clinical samples and produces lab-quality results using proprietary molecular chemistry and detection technologies. Prominex's diagnostic tools are designed to address a range of infectious diseases, including sexually transmitted infections, influenza, and bloodstream infections, thereby enhancing the accessibility and efficiency of patient diagnostics.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Another key candidate, FTX-6058, aims to increase fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. In addition to these programs, Fulcrum is exploring drug targets for other conditions such as Duchenne muscular dystrophy, Friedreich ataxia, myotonic dystrophy 1, and various neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma and MyoKardia to advance research and develop targeted therapies for pulmonary diseases and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum Therapeutics is committed to improving the lives of patients facing significant health challenges.

PACT Pharma, Inc. is engaged in developing personalized cell-based therapies aimed at treating cancer, specifically through neoantigen-specific adoptive TCR T-cell therapies for solid tumors. The company utilizes advanced bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying neoantigen peptides that provoke targeted T cell responses against cancer cells. By recognizing neo-epitopes, which are unique mutations in each patient's cancer, PACT Pharma creates autologous T cells engineered to specifically target and eliminate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is focused on innovative approaches to enhance cancer treatment through tailored immunotherapies.

Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.

Lyra Health, Inc. is a Burlingame, California-based company that operates a digital platform connecting employers with mental health care providers. Founded in 2015, Lyra Health aims to improve access to effective mental health care for employees by utilizing innovative matching technology. The platform enables members to find personalized care by connecting them to a curated network of therapists and coaches, facilitating live video therapy and offering digital self-care tools. Lyra Health assesses treatment outcomes using clinical measures, such as the PHQ-9 and GAD-7, to monitor symptom improvement for conditions like anxiety and depression. This approach has resulted in significantly higher engagement and better outcomes compared to traditional mental health plans. Through its services, Lyra Health helps employees navigate the mental health system, schedule appointments, and maintain support throughout their treatment journey.

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.

Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.

Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.